Studies have reported that KRAS mutation had no influence on clinical outcome in pediatric patients with AML, in AML patients under 60 years old, in patients with secondary AML or in patients with AML harboring CBFB-MYH11 fusions [81,82]. This evidence concerns the gene CBFB and acute myeloid leukemia.